J&J inks $6.5B Momenta buyout to bag autoimmune drug
Johnson & Johnson has struck a deal to buy Momenta Pharmaceuticals for $6.5B, giving J&J control of an anti-FcRn antibody that completed a phase 2 trial in myasthenia gravis earlier this year.
J&J’s willingness to pay that much reflects its belief that Momenta can give it multiple blockbuster launches. Nipocalimab is in clinical development in myasthenia gravis, warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of fetus and newborn. Momenta also has another asset, hyper-sialylated human immunoglobulin G m234, in the clinic in immune thrombocytopenia purpura (ITP).
